From: Ovarian cancer immunotherapy: opportunities, progresses and challenges
Antigen category | Antigens | Tumor type | Vaccine | Reference |
---|---|---|---|---|
Differentiation Antigens | Tyrosinase | Melanoma | Yes | Int J Cancer 1996;67:54[60] |
 | Melan- Mart-1 | Melanoma | Yes | Cancer J Sci Am 1997; 3:37[61] |
 | gp-100 | Melanoma | Yes | Nat Med 1998; 4:321[62] |
Overexpression/Amplification | HER-2/neu | Ovarian cancer Breast cancer | Yes | J Clin Oncol. 2002; 20:2624[13] |
Antigens | p53 | various tumors | Yes | J Immunol 1998; 160:328[63] Cancer Immunol Immunother. 2004; 53:633[64] |
Mutational Antigens | p53 | various tumors | Yes | J Clin Oncol 2005; 23:5099[65] |
 | Ras | various tumors | Yes | Int J Cancer 2001; 92:441[66] |
Cancer Testis Antigens | MAGE | Melanoma | Yes | Int J Cancer 1999; 80:219[67] |
 | NY-ESO-1 | Ovarian cancer | Yes | Clin Cancer Res. 2008; 14:2740[31] |
 | LAGE-1 | Ovarian cancer Melanoma Bladder cancer | No | Cancer Res. 2003; 63:6076[20] |
Glycolipid Antigens | MUC-1 | Adenocarcinoma | Yes | J. Clin. Invest. 1997; 100:2783[68] |
 | MUC-16 (CA125) | Ovarian cancer | Yes | Int J Cancer 2002; 98:737[69] Clin Cancer Res. 2004; 22:3507[70] |
Oncofetal Antigens | AFP | Germ cell tumors | No | Gynecol. Oncol. 2000; 77:203[71] |
 | CEA | Colorectal cancer | Yes | Ann Surg Oncol 1996; 3:495[72] |
 | PSA | Prostate cancer | Yes | Urology 1999; 53:260[73] |
Viral Antigens | HPV | Cervical cancer | Yes | Lancet 1996; 347:1523[74] |